The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Open accessAbstract
Overexpression of HER-2/neu correlates with poor survival of breast and ovarian cancer patients and induces resistance to tumor necrosis factor (TNF), which causes cancer cells to escape from host immune defenses. The mechanism of HER-2/neu-induced TNF resistance is unknown. Here we report that HER-2/neu activates Akt and NF-kappaB without extracellular stimulation. Blocking of the Akt pathway by a dominant-negative Akt sensitizes the HER-2/neu-overexpressing cells to TNF-induced apoptosis and inhibits IkappaB kinases, IkappaB phosphorylation, and NF-kappaB activation. Our results suggested that HER-2/neu constitutively activates the Akt/NF-kappaB anti-apoptotic cascade to confer resistance to TNF on cancer cells and reduce host defenses against neoplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797
PI3K: Downstream AKTion Blocks Apoptosis
Franke, T. F., Kaplan, D. R., & Cantley, L. C. (1997) · Cell · doi:10.1016/s0092-8674(00)81883-8 · Cited by 1,668
Cited by
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“…ErbB2-overexpressing cancer cells and Akt is inhibited after ErbB2 downregulation by trastuzumab, which is critical for tras-functions to dephosphorylate PIP 3 to PIP 2 , leading to Akt de-phosphorylation. tuzumab’s antitumor effect (Ignatoski et al., 2000; Yakes et al., 2002; Zhou et al., 2000).”
BackgroundThe protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581
Self-citationTargeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
Self-citationHER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Self-citationThe Role of Snail in EMT and Tumorigenesis
Wang, Y., Shi, J., Chai, K., Ying, X., & Zhou, B. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113136660102 · Cited by 875
Self-citationIκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
Hu, M. C.-T., Lee, D.-F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00302-2 · Cited by 868
Self-citationp53 represses c-Myc through induction of the tumor suppressor miR-145
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., & Mo, Y.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808042106 · Cited by 841
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Madrid, L. V., Mayo, M. W., Reuther, J. Y., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101103200 · Cited by 777
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Chronic immune activation and inflammation as the cause of malignancy
O'Byrne, K. J., & Dalgleish, A. G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1943 · Cited by 543
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., Hortobagyi, G. N., Yu, D., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.027 · Cited by 537
Self-citationCruceriu, D., Baldasici, O., Balacescu, O., & Berindan-Neagoe, I. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00489-1 · Cited by 524
Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways1
Dent, P., Yacoub, A., Contessa, J., Caron, R., Amorino, G., Valerie, K., Hagan, M. P., Grant, S., & Schmidt-Ullrich, R. (2003) · Radiation Research · doi:10.1667/0033-7587(2003)159[0283:sariao]2.0.co;2 · Cited by 463
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Self-citationNuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
Nephrin and CD2AP Associate with Phosphoinositide 3-OH Kinase and Stimulate AKT-Dependent Signaling
Huber, T. B., Hartleben, B., Kim, J., Schmidts, M., Schermer, B., Keil, A., Egger, L., Lecha, R. L., Borner, C., Pavenstädt, H., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4917-4928.2003 · Cited by 412
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
Interaction with Podocin Facilitates Nephrin Signaling
Huber, T. B., Köttgen, M., Schilling, B., Walz, G., & Benzing, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100452200 · Cited by 378
Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Self-citationβ-catenin interacts with and inhibits NF-κB in human colon and breast cancer
Deng, J., Miller, S. A., Wang, H.-Y., Xia, W., Wen, Y., Zhou, B. P., Li, Y., Lin, S.-Y., & Hung, M.-C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00154-x · Cited by 372
Self-citationApoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein
Li, Y., Upadhyay, S., Bhuiyan, M., & Sarkar, F. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202650 · Cited by 319
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Self-citationMapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 312
Zhou, X., Tan, M., Stone Hawthorne, V., Klos, K. S., Lan, K.-H., Yang, Y., Yang, W., Smith, T. L., Shi, D., & Yu, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0112 · Cited by 312
Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., De Cremoux, P., Bertheau, P., Badoual, C., Vielh, P., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 302
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Self-citationHinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., & Scheidereit, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020062 · Cited by 266
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L., & Bold, R. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601396 · Cited by 260
Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402305200 · Cited by 194
Zhang, B., Spandau, D. F., & Roman, A. (2002) · Journal of Virology · doi:10.1128/jvi.76.1.220-231.2002 · Cited by 85
Metadata
- Authors
- Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-03
- Volume
- 275
- Issue
- 11
- Pages
- 8027-8031
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2052512448
- Cited by
- 371
- References
- 28
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.